Skip to content

Ketamine: all studies

Page 163 of 449: studies 1,621 to 1,630 of 4,483, newest first. Back to the ketamine overview

Research

Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study.

Psychopharmacology July 1, 2023 Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin et al. 26 citations

Ketamine and its enantiomers are widely researched and increasingly used to treat mental disorders, especially treatment-resistant depression. The phenomenology of ketamine-induced experiences and their relation to its psychotherapeutic potential have not yet been systematically investigated. To describe the phenomenology of patient experiences during oral esketamine treatment for...

Exploring the Promise of Ketamine Therapy for Autism: Benefits and Brain Changes

Journal of Clinical Research and Case Studies June 30, 2023 Ryan D Ward

Autism is a neurodevelopmental disorder that affects communication and social interaction abilities. While there are various therapeutic options available for autism, there is growing evidence suggesting that ketamine therapy could be a promising treatment for autism spectrum disorder (ASD). Ketamine is a dissociative anesthetic that has been used for decades in anesthesia and pain management,...

Suicide prevention and ketamine: insights from computational modeling

Frontiers in Psychiatry June 30, 2023 Colleen E. Charlton, Povilas Karvelis, Roger S McIntyre et al. 7 citations

Suicide is a pressing public health issue, with over 700,000 individuals dying each year. Ketamine has emerged as a promising treatment for suicidal thoughts and behaviors (STBs), yet the complex mechanisms underlying ketamine’s anti-suicidal effect are not fully understood. Computational psychiatry provides a promising framework for exploring the dynamic interactions underlying suicidality and...

DOI: 10.3389/fpsyt.2023.1214018 (opens in new tab) Full text (opens in new tab) Computational modeling Generative models Innovative approach Powerful tool +11

Ketamine Pioneer Krystal Receives 2023 Nasrallah Family Award

Psychiatric News June 28, 2023 Nick Zagorski

Back to table of contents Previous article Next article Annual MeetingFull AccessKetamine Pioneer Krystal Receives 2023 Nasrallah Family AwardNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:28 Jun 2023https://doi.org/10.1176/appi.pn.2023.07.7.44AbstractKrystal’s work with ketamine has increased our understanding of the biology of both depression and schizophrenia...

Decreased Thalamic Activity Is a Correlate for Disconnectedness during Anesthesia with Propofol, Dexmedetomidine and Sevoflurane But Not S-Ketamine.

Journal of Neuroscience June 28, 2023 Oskari Kantonen, Lauri Laaksonen, Michael Alkire et al.

Establishing the neural mechanisms responsible for the altered global states of consciousness during anesthesia and dissociating these from other drug-related effects remains a challenge in consciousness research. We investigated differences in brain activity between connectedness and disconnectedness by administering various anesthetics at concentrations designed to render 50% of the subjects...

DOI: 10.1523/jneurosci.2339-22.2023 (opens in new tab) Full text (opens in new tab) Anesthesia Consciousness Disconnected Neuroimaging +1

Effects of cannabis use on antidepressant treatment response to repetitive transcranial magnetic stimulation and ketamine

medRxiv Preprint Server June 28, 2023 Mohammad Ali Shenasa, Houtan Totonchi Afshar, Eric A. Miller et al. preprint

Background The antidepressant effects of ketamine and repetitive transcranial magnetic stimulation (rTMS) are hypothesized to rely on mechanisms of long-term-potentiation and synaptic plasticity. Cannabis, via activation of CB1 receptors has been shown to impair synaptic plasticity, suggesting that cannabis use might moderate the antidepressant effects of ketamine and/or rTMS.

Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review

Frontiers in Psychiatry June 26, 2023 Simon Zhornitsky, Henrique Nunes Pereira Oliva, Laura A. Jayne et al. 12 citations

Background Ketamine and psychedelics have abuse liability. They can also induce “transformative experiences” where individuals experience enhanced states of awareness. This enhanced awareness can lead to changes in preexisting behavioral patterns which could be beneficial in the treatment of substance use disorders (SUDs). Preclinical and clinical studies suggest that ketamine and psychedelics...

Age, Dose, and Locomotion: Decoding Vulnerability to Ketamine in C57BL/6J and BALB/c Mice.

Biomedicines June 25, 2023 Wen-Chien Chen, Tzong-Shi Wang, Fang-Yu Chang et al. 12 citations

Ketamine has been abused as a psychedelic agent and causes diverse neurobehavioral changes. Adolescence is a critical developmental stage but vulnerable to substances and environmental stimuli. Growing evidence shows that ketamine affects glutamatergic neurotransmission, which is important for memory storage, addiction, and psychosis. To explore diverse biological responses, this study was...

Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity

The World Journal of Biological Psychiatry June 20, 2023 Maria Gałuszko‐węgielnik, Katarzyna Jakuszkowiak‐wojten, Alina Wilkowska et al. 9 citations

OBJECTIVES: Borderline personality disorder (BPD) and bipolar disorder (BD) often co-occur and frequently do not respond adequately to traditional antidepressant treatments. Ketamine has shown rapid antidepressant and anti-suicidal effects. However, there is limited literature on the safety and tolerance of using ketamine to treat patients with comorbid BD and BPD. METHODS: This case presents a...

A single dose of ketamine enhances early life stress-induced aggression with no effect on fear memory, anxiety-like behavior, or depression-like behavior in mice

Behavioral Neuroscience June 15, 2023 Caitlyn J Bartsch, Sophia Aaflaq, Jessica T. Jacobs et al.

Ketamine is a dissociative anesthetic that has been shown to have antidepressant effects in humans and has been proposed as a potential treatment for mood disorders such as PTSD and aggression. However, previous studies from our lab and others have demonstrated that ketamine’s effects are highly context- and dose-dependent. In a recent study, we found that 10 mg/kg ketamine could exacerbate the...